Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05391893 · ClinicalTrials.gov registry record · Phase 4
Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
A Phase 4 study of Atrial Fibrillation and Atrial Flutter, sponsored by Corewell Health South.
- Completed
- Registry status
- Phase 4
- Development phase
- 444
- Enrollment target
- 1
- Study location
NCT05391893 is a Phase 4 study of Atrial Fibrillation and Atrial Flutter that has completed, run by Corewell Health South. The registered enrollment target is 444 participants, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05391893, a Phase 4 study of Atrial Fibrillation and Atrial Flutter, has completed, sponsored by Corewell Health South.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 444 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Department of Spectrum Health Lakeland. Secondary outcome is to measure if oral diltiazem is an effective HR controlling agent in AF RVR and Flutter.
Conditions Studied
Interventions
- DRUG Oral
- DRUG Intravenous drug
Study Locations (1)
Michigan
- Matthew Hysell - Saint Joseph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2020-06-19 |
| Est. Completion | 2023-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05391893
The ClinicalTrials.gov registry entry for NCT05391893 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (85% lower). The listed sponsor is Corewell Health South, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Oral is the first listed.
NCT05391893 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05391893 about?
NCT05391893 is a clinical study titled "Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation". The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Department of Spectrum Health Lakeland. Secondary outcome is to measure if oral diltiazem is an effectiv...
What is the current status of trial NCT05391893?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 444 participants. The study started on 2020-06-19. Estimated completion is 2023-04-01.
What conditions does trial NCT05391893 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter.
What interventions are being tested in trial NCT05391893?
The interventions under investigation include: Oral (DRUG), Intravenous drug (DRUG).
Who is sponsoring clinical trial NCT05391893?
This trial is sponsored by Corewell Health South, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05391893 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
ACTIVE NOT RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.